LULU, ARNA, MTSN - CRWESelect.com Stock News! Lululemon Athletica, Arena Pharmaceuticals, Mattson Technology (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) January 10, 2012 -- To view video, and read the full article visit URL http://crweselect.com/28120/stock-alerts/lulu-arna-mtsn-crweselectcom-stock-news-lululemon-athletica-arena-pharmaceuticals-mattson-technology-video-included-inside/

Lululemon Athletica Inc. (NASDAQ:LULU)

LULU announced today that the Company is raising its guidance for the fourth quarter of fiscal 2011 ending January 29, 2012. For the fourth quarter of fiscal 2011, the Company now expects diluted earnings per share to be in the range of $0.47 to $0.49 as compared to its previous guidance range for diluted earnings per share of $0.40 to $0.42. The Company's improved guidance reflects stronger than anticipated net revenue for the quarter. The Company now expects net revenue to be in the range of $358 million to $363 million for the fourth quarter of fiscal 2011.

LULU is a yoga-inspired athletic apparel company that creates components for people to live a long, healthy and fun life. By producing products that help keep people active and stress free, lululemon believes that the world will be a better place. Setting the bar in technical fabrics and functional designs, lululemon works with yogis and athletes in local communities for continuous research and product feedback.

For more information about LULU please visit http://www.lululemon.com

****

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

ARNA and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has accepted for filing and review Arena's resubmission of the New Drug Application (NDA) for lorcaserin. Lorcaserin is an investigational new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism.

ARNA is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

For more information about ARNA please visit http://www.arenapharm.com

****

Mattson Technology, Inc. (NASDAQ:MTSN)

MTSN, announced today that it has won acceptance for its Helios® XP rapid thermal processing (RTP) system from another leading semiconductor manufacturer. The Helios XP, which was selected by the customer based on its excellent processing performance and lower cost-of-ownership, is now in volume production of advanced logic chips.

MTSN designs, manufactures and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits. They are a leading supplier of plasma and rapid thermal processing equipment to the global semiconductor industry, and operate in three primary product sectors: Dry Strip, Rapid Thermal Processing and Etch. Through manufacturing and design innovation, they have produced technologically advanced systems that provide productive and cost-effective solutions for customers fabricating current- and next-generation semiconductor devices.

For more information about MTSN please visit http://www.mattson.com/

To read the full article visit URL http://crweselect.com/28120/stock-alerts/lulu-arna-mtsn-crweselectcom-stock-news-lululemon-athletica-arena-pharmaceuticals-mattson-technology-video-included-inside/

****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

LULUcrweselect0110
ARNAcrweselect0110
MTSNcrweselect0110

Arena Pharmaceuticals     arna     Lorcaserin     Lulu     Lululemon Athletica     Mattson Technology     MTSN     select